All In Biotech

Drug Trial Radar · NCT00717470

A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection

A Multicenter, Four Arm, Randomized, Open Label Clinical Study Investigating Optimized Dosing in a Prograf®-/Advagraf®-Based Immunosuppressive Regimen in Kidney Transplant Subjects (OSAKA Study)

Last checked: Nov 19, 2026Latest source record: Nov 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,252 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,252

Actual

Start

May 14, 2008

Primary completion

Mar 2, 2010

Study completion Mar 2, 2010

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Jul 17, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare how well the new formulation of Tacrolimus® used once daily, in combination with other drugs helps prevent the rejection of a new kidney after transplantation compared to the twice daily dose of Tacrolimus

Conditions

  • Kidney Transplantation

Interventions

  • Prograf®Drug

    oral

  • Advagraf®Drug

    oral

  • Mycophenolate MofetilDrug

    oral

  • SimulectDrug

    oral

  • methylprednisolone / prednisoneDrug

    oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy failure rateTime frame: 24 weeks

Locations

110 sites in 22 countries. Site status is shown where the registry gives one.

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Córdoba, Argentina

  • Site not named

    Innsbruck, Austria

  • Site not named

    Linz, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Brussels, Belgium

  • Site not named

    Brussels, Belgium

  • Site not named

    Ghent, Belgium

  • Site not named

    Leuven, Belgium

  • Site not named

    Brno, Czechia

  • Site not named

    Hradec Kravlove, Czechia

  • Site not named

    Ostrava, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Angers, France

  • Site not named

    Bordeaux, France

  • Site not named

    Brest, France

  • Site not named

    Créteil, France

  • Site not named

    La Tronche, France

  • Site not named

    Le Kremlin-Bicêtre, France

  • Site not named

    Limoges, France

  • Site not named

    Lyon, France

  • Site not named

    Nantes, France

  • Site not named

    Nice, France

  • Site not named

    Paris, France

  • Site not named

    Paris, France

  • Site not named

    Paris, France

  • Site not named

    Rennes, France

  • Site not named

    Saint-Etienne, France

  • Site not named

    Strasbourg, France

  • Site not named

    Suresnes, France

  • Site not named

    Toulouse, France

  • Site not named

    Tours, France

  • Site not named

    Vandœuvre-lès-Nancy, France

  • Site not named

    Aachen, Germany

  • Site not named

    Berlin, Germany

  • Site not named

    Essen, Germany

  • Site not named

    Frankfurt, Germany

  • Site not named

    Freiburg I. Br, Germany

  • Site not named

    Halle, Germany

  • Site not named

    Hamburg, Germany

Showing 40 of 110 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.